MarketLens

Stock Analysis Investment Ideas

Amgen's Core Strength Outweighs Early Obesity Drug Setback

2 months ago

SHARE THIS ON:

Amgen's Core Strength Outweighs Early Obesity Drug Setback

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

What's Driving Amgen's Recent Volatility

What's Driving Amgen's Recent Volatility

4 months ago

SoFi's Unseen Strength: Why Institutional Conviction Outweighs Insider Noise

SoFi's Unseen Strength: Why Institutional Conviction Outweighs Insider Noise

3 months ago

What Does Rep. Salazar's Amgen Purchase Signify for Biotech Investors

What Does Rep. Salazar's Amgen Purchase Signify for Biotech Investors

5 months ago

Is Rhythm Pharmaceuticals Poised for a Breakthrough in Hypothalamic Obesity

Is Rhythm Pharmaceuticals Poised for a Breakthrough in Hypothalamic Obesity

7 months ago

Category

Top Featured Pro Only Stock Analysis Investment Ideas ETFs Crypto

You may also like

Stock News•1 months ago

Structure Therapeutics: The Amylin Data Changes The Math

Structure Therapeutics' lead oral obesity drug aleniglipron showed 16.2% weight loss at 72 weeks, with low discontinuations and no DILI, de-risking its profile. ACCG-2671, an oral amylin agonist, now ...

Stock News•1 months ago

GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)

Amgen and Regeneron could benefit from soaring GLP-1 demand, as both develop differentiated candidates. Amgen's product and Regeneron's pipeline may capture market share if trials succeed.

Stock News•2 months ago

Amgen Lifts Outlook on Strong Drug Sales, to End Early Development of Obesity Treatment

Amgen raised full-year revenue guidance to $38.2B–$39.4B on strong drug sales, but halted early development of its phase 1 obesity treatment, citing program changes.

Breaking News

Biotech & Pharma

Analyst Ratings

Banking Sector Health

Corporate Earnings

Defense Industry

Dividend Stocks

Management Changes

Shareholder Rights

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

2 months ago

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

2 months ago

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

2 months ago

Top Headlines

Stock News•1 hour ago

Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today

Stock News•1 hour ago

Why the Market Dipped But Microsoft (MSFT) Gained Today

Stock News•1 hour ago

Nvidia (NVDA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Stock News•1 hour ago

Tesla (TSLA) Declines More Than Market: Some Information for Investors

Stock News•1 hour ago

Amazon Will Be The Final Winner Of The AI Race With Anthropic's Help